Text:
"x-ray" "x-ray diffract? " or "XRD" or "XRPD"
"cetirizine" "dihydrochloride"
or "x-ray powder diffract?"

10729856

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:53:53 ON 18 NOV 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:54:05 ON 18 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 NOV 2006 HIGHEST RN 913607-70-2
DICTIONARY FILE UPDATES: 17 NOV 2006 HIGHEST RN 913607-70-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10729856.str



chain nodes :
7 8 9 10 11 12 25
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 19 20 21 22 23 24

10729856

chain bonds :
3-12 6-7 7-8 8-9 9-10 10-11 12-13 12-14 17-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-20 13-24 14-15 14-19 15-16 16-17 17-18
18-19 20-21 21-22 22-23 23-24
exact/norm bonds :
1-2 1-6 2-3 3-4 3-12 4-5 5-6 6-7 8-9 9-10
exact bonds :
7-8 10-11 12-13 12-14 17-25
normalized bonds :
13-20 13-24 14-15 14-19 15-16 16-17 17-18 18-19 20-21 21-22 22-23 23-24

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:54:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           93 TO      587
PROJECTED ANSWERS:               4 TO      200

L2            4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:54:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      351 TO ITERATE

100.0% PROCESSED      351 ITERATIONS                                39 ANSWERS
SEARCH TIME: 00.00.01

L3            39 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     166.94     167.15

FILE 'HCAPLUS' ENTERED AT 16:54:33 ON 18 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Nov 2006  VOL 145 ISS 22
FILE LAST UPDATED: 17 Nov 2006  (20061117/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4          1011 L3

=> s l4 and cyrstal?
            326 CYRSTAL?
L5            0 L4 AND CYRSTAL?

=> s l4 and crystal?
         1792725 CRYSTAL?
L6           17 L4 AND CRYSTAL?

=> d ed abs ibib hitstr 1-17
```

L6 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 May 2006
AB There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insol. polymer and at least one gastrosol. inorg. or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach. Thus, microgranules were prepared containing cetirizine hydrochloride hydrochlororide 20 %, microcryst. cellulose 70 % and Methocel K100LV at 10 % were granulated. The microgranules (700 mg) obtained above were microencapsulated using ethylcellulose 300 g and calcium carbonate 150 g.
ACCESSION NUMBER: 2006:469354 HCAPLUS
DOCUMENT NUMBER: 144:474945
TITLE: Taste-masked pharmaceutical compositions comprising water-insol. polymer and a pore-former prepared by coacervation
INVENTOR(S): Lai, Jin-Wang; Qian, Ken Kangyi; Venkatesh, Gopi M.
PATENT ASSIGNEE(S): Eurand Pharmaceuticals Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006105038	A1	20060518	US 2005-213266	20050826
WO 2006055142	A2	20060526	WO 2005-US37084	20051013
WO 2006055142	A3	20060720		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-627525P P 20041112
US 2005-213266 A 20050826

IT 83881-52-1, Cetirizine hydrochloride

L6 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste-masked pharmaceutical compns. comprising water-insol. polymer and a pore-former)
RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 83881-51-0, Cetirizine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste-masked pharmaceutical compns. comprising water-insol. polymer and a pore-former)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 May 2006
AB There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insol. polymer and one or more gastrosol. inorg. or organic pore-formers (practically insol. in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach. Diphenhydramine hydrochloride (375 g) was slowly added to an aqueous solution of 41.8 g polyvinylpyrrolidone and 1667 g of purified water and mixed well. Sugar spheres (60-80 mesh, 1470 g) were coated with the above formulation and the drug containing pellets were dried, and a seal coat of Opadry Clear for a weight gain of 4% was applied on the drug-layered beads. Thus, 1000 g of drug-layered beads produced above were coated with a membrane comprising 227.3 g of EC-10, 22.7 g of Myvacet 9-45 (diacetylatedmonoglyceride) and 68.2 g of calcium carbonate dissolved/suspended in 3916.6 g of 95/5 acetone/water. The coated beads were dried and their dissoln. profiles was studied.
ACCESSION NUMBER: 2006:410144 HCAPLUS
DOCUMENT NUMBER: 144:440104
TITLE: Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
INVENTOR(S): Lai, Jin-Wang; Venkatesh, Gopi M.; Qian, Ken Kangyi
PATENT ASSIGNEE(S): Eurand Pharmaceuticals Limited, Ire.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006047493	A2	20060504	WO 2005-US38328	20051021

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006105039	A1	20060518	US 2005-256653	20051021

PRIORITY APPLN. INFO.: US 2004-621144P P 20041021

L6 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 83881-51-0, Cetirizine 83881-52-1, Cetirizine dihydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste-masked pharmaceutical compns. with gastrosol. pore-formers)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L6 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Apr 2006
AB There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 s forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insol. and gastro-soluble polymers release not less than about 60% of the dose is in the stomach in about 30 min, thus maximizing the probability of achieving bioequivalence to the reference immediate-release product having rapid onset of action (short Tmax). A process for preparing such compns. for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed. For example, drug-layered cetirizine dihydrochloride beads (drug load: 8.4%) were prepared by coating sugar spheres with an aqueous solution of cetirizine dihydrochloride and polyvinylpyrrolidone to obtain pellets and seal coating the pellets with Opadry Clear. The beads were then coated with Et cellulose/Eudragit E100 with Myvacet 9-45/talc to give taste-masked beads. The taste-masked beads coated at 20% released 13% drug in 5 min using the USP Apparatus 2. Taste-masked beads at 20% coating, rapidly-dispersing microgranules, crospovidone, flavor, and Aspartame would be blended and compressed into orally disintegrating tablets containing 10 mg of cetirizine dihydrochloride.
ACCESSION NUMBER: 2006:341597 HCAPLUS
DOCUMENT NUMBER: 144:376503
TITLE: Taste-masked pharmaceutical compositions
INVENTOR(S): Venkatesh, Gopi M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006078614	A1	20060413	US 2005-248596		20051012
PRIORITY APPLN. INFO.:			US 2004-617737P	P	20041012

IT 83881-51-0, Cetirizine 83881-52-1, Cetirizine dihydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally disintegrating tablets comprising taste-masked microparticles and rapidly-dispersing microgranules)
RN 83881-51-0 HCAPLUS

L6 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L6 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 17 Jun 2005
AB A multiparticulate for controlled release of a crystalline drug comprises a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a Poloxamer, wherein at least 70 weight% of the drug in the multiparticulate is crystalline Thus, azithromycin-containing multiparticulates were prepared via a melt-congeal process from a mixture containing azithromycin/Compritol 888 ATO/Pluronic (50:40:10) forming a preblend and extrusion of the preblend at a feed rate of 130 g/min. More than 90 weight% of the azithromycin in the multiparticulates was crystalline dihydrate. The release rate of azithromycin from the multiparticulates was 32, 67, 90, 99, 99, and 100% in 5, 15, 30, 60, 120, and 180 min, resp.
ACCESSION NUMBER: 2005:523256 HCAPLUS
DOCUMENT NUMBER: 143:65406
TITLE: Multiparticulate crystalline drug compositions containing a Poloxamer and a glyceride
INVENTOR(S): Appel, Leah Elizabeth; Crew, Marshall David; Friesen, Dwayne Thomas; Herbig, Scott M.; Lo, Julian Belknap; Lyon, David Keith; McCray, Scott Bladwin; Ray, Roderick Jack; West, James Blair
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005053652	A1	20050616	WO 2004-IB3808		20041122
WO 2005053652	C1	20050804			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005181062	A1	20050818	US 2004-4168		20041203
PRIORITY APPLN. INFO.:			US 2003-527329P	P	20031204

IT 83881-51-0, Cetirizine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiparticulate compns. containing glyceride and Poloxamer for controlled release of crystalline drug)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

- compos -

11/004,168

L6 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 28 Jan 2005
AB A novel crystalline form of cetirizine monohydrochloride and processes for making the crystalline form as well as compns., pharmaceutical compns., and methods utilizing the crystalline form are described. A process for preparation of a crystalline form of cetirizine monohydrochloride, comprises (1) providing a solid residue of crude cetirizine monohydrochloride; (2) contacting the crude residue with a ketone solvent to cause separation of a solid mass; and (3) isolating the solid mass thereby obtaining the crystalline form of cetirizine monohydrochloride. Tablets for the treatment of allergic syndromes were formulated containing crystalline cetirizine monohydrochloride 10, CaCO3 500, PVP 17, Avicel 15, mannitol 400, maltodextrin 15, aspartame 3, and aroma 20 mg each.
ACCESSION NUMBER: 2005:78236 HCAPLUS
DOCUMENT NUMBER: 142:162672
TITLE: Crystalline cetirizine monohydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Rao, Uppala Venkata Bhaskara; Reddy, Konda Srinivasa
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005020608	A1	20050127	US 2004-809192		20040325
PRIORITY APPLN. INFO.:			IN 2003-MA252	A	20030325

IT 798544-25-9P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
RN 798544-25-9 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)



IT 83881-52-1P, Cetirizine dihydrochloride
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L6 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 31 Dec 2004
AB An amorphous form of the antiallergic compound cetirizine dihydrochloride, prepared by the base-promoted hydrolysis of the corresponding amide of certizine, extraction, followed by HCl salification, is prepared as are pharmaceutical compns. utilizing this crystalline form.
ACCESSION NUMBER: 2005:2182 HCAPLUS
DOCUMENT NUMBER: 142:93859
TITLE: Process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Rao, Uppala Venkata Bhaskara; Reddy, Konda Srinivasa
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004266787	A1	20041230	US 2004-809193		20040325
PRIORITY APPLN. INFO.:			IN 2003-MA253	A	20030325

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(in a process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)



IT 83881-52-1P, Cetirizine dihydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride)
RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

L6 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Jun 2004
AB Crystalline polymorphic forms of the levorotatory and dextrorotatory cetirizine
dihydrochloride salts are prepared by dissolving the salts in an a ketone-containing solvent (e.g., aqueous acetone), cooling the solution, and
collecting the crystalline precipitate
ACCESSION NUMBER: 2004:493694 HCAPLUS
DOCUMENT NUMBER: 141:54360
TITLE: Polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation
INVENTOR(S): Reddy, Manne Satyanarayana; Srinivasan, Thirumalai Rajan; Uppala, Venkata Bhaskara Rao; Vaddadi, Pattabhi
Ramayya; Joga, Rajender
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050647	A2	20040617	WO 2003-US38494	20031204
WO 2004050647	A3	20040902		
WO 2004050647	C1	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488114	AA	20040617	CA 2003-2488114	20031204
AU 2003297640	A1	20040623	AU 2003-297640	20031204
US 2004186112	A1	20040923	US 2003-729856	20031204
CN 1692105	A	20051102	CN 2003-80100943	20031204
PRIORITY APPLN. INFO.:			IN 2002-MA908 A	20021204
			WO 2003-US38494 W	20031204

IT 130018-87-0P 163837-48-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorphic crystalline forms of dihydrochloride salts of cetirizine and
processes for their preparation)

L6 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 130018-77-8 HCAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 130018-87-0 HCAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

RN 163837-48-7 HCAPLUS
CN Acetic acid, [2-[4-[(S)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

IT 130018-76-7P, Dextrocetirizine 130018-77-8P, Levocetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(polymorphic crystalline forms of dihydrochloride salts of cetirizine and
processes for their preparation from)
RN 130018-76-7 HCAPLUS
CN Acetic acid, [2-[4-[(S)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L6 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Apr 2004
AB A chewing gum comprising at least two different biodegradable polymers exhibits an improved texture prior to any adding of for example softeners.
It has been realized that the desired chewing gum texture properties, contrary to every expectation and any prior art disclosures, may be actually be obtained when combining biodegradable chewing gum polymers, for example in the gum base or in the final gum. Thus, a peppermint chewing gum formulation contains gum base 40, sorbitol 48.6, lycasin 3, peppermint oil 1.5, menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, and xylitol 6 weight%.
ACCESSION NUMBER: 2004:290440 HCAPLUS
DOCUMENT NUMBER: 140:320320
TITLE: Chewing gum comprising at least two different biodegradable polymers
INVENTOR(S): Andersen, Lone; Wittorff, Helle
PATENT ASSIGNEE(S): Gumlink A/S, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028268	A1	20040408	WO 2002-DK627	20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500976	AA	20040408	CA 2002-2500976	20020924
AU 2002340774	A1	20040419	AU 2002-340774	20020924
BR 2002015888	A	20050726	BR 2002-15888	20020924
EP 1562439	A1	20050817	EP 2002-774470	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1668208	A	20050914	CN 2002-829650	20020924
JP 2006500041	T2	20060105	JP 2004-538758	20020924
CA 2499998	AA	20040408	CA 2003-2499998	20030924
WO 2004028270	A1	20040408	WO 2003-DK626	20030924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003266215	A1	20040419	AU 2003-266215	20030924
EP 1545234	A1	20050629	EP 2003-798088	20030924

L6 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003014678	A	20050802	BR 2003-14678		20030924
JP 2006500044	T2	20060105	JP 2004-538771		20030924
CN 1728949	A	20060201	CN 2003-822649		20030924
US 2005244538	A1	20051103	US 2005-88109		20050323
US 2006240143	A1	20061026	US 2005-528926		20051216
PRIORITY APPLN. INFO.:			WO 2002-DK627	W	20020924
			WO 2003-DK626	W	20030924

IT 83881-51-0 130018-77-8
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(chewing gum comprising at least two different biodegradable polymers)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)



RN 130018-77-8 HCAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Apr 2004
AB A chewing gum comprises at least one biodegradable polyester copolymer obtained by the polymerization of two or more cyclic esters by ring-opening. At least one biodegradable polyester copolymer has a mol. weight of less than 150000 g/mol and the chewing gum further comprises chewing gum ingredients. An improved release of chewing gum ingredients has been obtained when a texture acceptable biodegradable polyester copolymer are applied as a chewing gum polymer. Thus, a chewing gum formulation contains gum base 40, sorbitol 48.6, lycasin 3, peppermint oil 1.5, menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, and xylitol 5 weight%.
ACCESSION NUMBER: 2004:290439 HCAPLUS
DOCUMENT NUMBER: 140:320319
TITLE: Chewing gum having improved release of chewing gum ingredients
INVENTOR(S): Andersen, Lone; Wittorf, Helle
PATENT ASSIGNEE(S): Gumlink A/S, Den.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028267	A1	20040408	WO 2002-DK626	20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500026	AA	20040408	CA 2002-2500026	20020924
AU 2002342579	A1	20040419	AU 2002-342579	20020924
EP 1549153	A1	20050706	EP 2002-779229	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015887	A	20050726	BR 2002-15887	20020924
CN 1668206	A	20050914	CN 2002-829648	20020924
JP 2006500040	T2	20060105	JP 2004-538757	20020924
US 2006099300	A1	20060511	US 2005-529133	20050906
PRIORITY APPLN. INFO.:			WO 2002-DK626 W	20020924

IT 83881-51-0 130018-77-8
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(chewing gum having improved release of chewing gum ingredients)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-

L6 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 130018-77-8 HCAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Apr 2004
AB A chewing gum comprises at least one biodegradable polymer, wherein the mol. weight of said polymer is at least 105000 g/mol (Mn). According to the invention, it has moreover been realized that this problem may be effectively dealt with by increasing the mol. weight of at least one of the biodegradable polymers in the chewing gum when compared to conventional chewing gum polymers and thereby increasing the robustness of the chewing gum with respect to softeners, emulsifiers and e.g. flavor. Thus, chewing gum ingredients contain gumbase 40, sorbitol powder 45.6, lycasin 3, peppermint oil 1.5, menthol crystal 0.5, aspartame 0.2, acesulfame 0.2, and xylitol 6%.
ACCESSION NUMBER: 2004:290438 HCAPLUS
DOCUMENT NUMBER: 140:320318
TITLE: Biodegradable chewing gum comprising at least one high molecular weight biodegradable polymer
INVENTOR(S): Andersen, Lone; Wittorf, Helle
PATENT ASSIGNEE(S): Gumlink A/S, Den.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028266	A1	20040408	WO 2002-DK625	20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500022	AA	20040408	CA 2002-2500022	20020924
AU 2002342578	A1	20040419	AU 2002-342578	20020924
EP 1542542	A1	20050622	EP 2002-779228	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015890	A	20050726	BR 2002-15890	20020924
CN 1668209	A	20050914	CN 2002-829651	20020924
JP 2006500039	T2	20060105	JP 2004-538756	20020924
US 2006165842	A1	20060727	US 2005-528927	20051216
PRIORITY APPLN. INFO.:			WO 2002-DK625 W	20020924

IT 83881-51-0, Cetirizine 130018-77-8, Levocetirizine
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(low moisture chewing gum comprising biodegradable polymer)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 130018-77-8 HCAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Apr 2004
AB Chewing gum comprises at least one biodegradable polymer and chewing gum ingredients. Chewing gum contains less than about 2.0 weight percent water of the chewing gum. The biodegradable chewing gum having low moisture was provided in combination with an initial acceptable texture. Thus, a chewing gum formulation contains gum base 40, sorbitol 48.6, maltitol syrup 3, peppermint oil 1.5, menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, xylitol 6, and water 1.5%.
ACCESSION NUMBER: 2004:290437 HCAPLUS
DOCUMENT NUMBER: 140:320317
TITLE: Low moisture chewing gum comprising biodegradable polymer
INVENTOR(S): Andersen, Lone; Wittorf, Helle
PATENT ASSIGNEE(S): Gumlink A/S, Den.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028265	A1	20040408	WO 2002-DK624	20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500000	AA	20040408	CA 2002-2500000	20020924
AU 2002342577	A1	20040419	AU 2002-342577	20020924
EP 1542541	A1	20050622	EP 2002-779227	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015889	A	20050726	BR 2002-15889	20020924
CN 1703150	A	20051130	CN 2002-829647	20020924
JP 2006500038	T2	20060105	JP 2004-538755	20020924
US 2006246174	A1	20061102	US 2005-529137	20050906
PRIORITY APPLN. INFO.:			WO 2002-DK624 W	20020924

IT 83881-51-0 130018-77-8
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(low moisture chewing gum comprising biodegradable polymer)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 130018-77-8 HCAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Apr 2004
AB Degradable chewing gum polymer is a polymer polymerized from at least one trifunctional or higher functional initiator, at least two different monomers forming the backbone of the polymer and at least one monomer selected from the group of carbonate monomers. It has been realized that a certain degree of branching of the backbone is needed to obtain a final improved performance, when the polymer, preferably the elastomer, is incorporated in a chewing gum. It has moreover been realized that the obtained degree of branching needs and may actually be carefully controlled in order to avoid too much branching-induced crosslinking. Thus, a chewing gum formulation contains gum base 40, sorbitol 48.6, lycasin 3, peppermint oil 1.5, menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, and xylitol 6 weight%.
ACCESSION NUMBER: 2004:287754 HCAPLUS
DOCUMENT NUMBER: 140:320316
TITLE: Degradable chewing gum polymer
INVENTOR(S): Andersen, Lone; Wittorf, Helle; Storey, Robson; Desai, Ganesh S.
PATENT ASSIGNEE(S): Gumlink A/S, Den.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028269	A1	20040408	WO 2002-DK628	20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501059	AA	20040408	CA 2002-2501059	20020924
AU 2002342580	A1	20040419	AU 2002-342580	20020924
EP 1549154	A1	20050706	EP 2002-779230	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015885	A	20050726	BR 2002-15885	20020924
CN 1668207	A	20050914	CN 2002-829649	20020924
JP 2006500445	T2	20060105	JP 2004-538759	20020924
US 2006121156	A1	20060608	US 2005-528930	20050906
PRIORITY APPLN. INFO.:			WO 2002-DK628 W	20020924

IT 83881-51-0 130018-77-8
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(biodegradable chewing gum polymer prepared by ring-opening polymerization)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 130018-77-8 HCAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 Dec 2003
AB A novel, amorphous form of [2-[4-[(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride, suitable for pharmaceutical formulations, is prepared and X-ray diffraction patterns for
it are presented.
ACCESSION NUMBER: 2003:991495 HCAPLUS
DOCUMENT NUMBER: 140:47519
TITLE: Process for the preparation of an amorphous form of [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride)
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Shankar, Ranga Ravi; Vardhan, Sunkara Vishnu
PATENT ASSIGNEE(S): Dr.Reddy's Laboratories Ltd., India; Dr.Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104212	A1	20031218	WO 2003-US17600	20030604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003238883	A1	20031222	AU 2003-238883	20030604
PRIORITY APPLN. INFO.:			IN 2002-MA425 A	20020605
			WO 2003-US17600 W	20030604

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in a process for the preparation of an amorphous form of [2-[4-[(4-chlorophenyl)phenylmethyl]-1- piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 83881-52-1P, Cetirizine dihydrochloride
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
(Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(process for the preparation of an amorphous form of [2-[4-[(4-chlorophenyl)phenylmethyl]-1- piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 Dec 2003
AB A crystalline form of cetirizine dihydrochloride (I), prepared by the salification of cetirizine with isopropanolic hydrogen chloride, having a defined X-ray diffraction pattern is presented, and pharmaceutical compns.
containing I are presented.
ACCESSION NUMBER: 2003:991494 HCAPLUS
DOCUMENT NUMBER: 140:42205
TITLE: Preparation of crystalline [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride)
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Shankar, Ranga Ravi; Vardhan, Sunkara Vishnu
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104211	A2	20031218	WO 2003-US17672	20030604
WO 2003104211	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003237394	A1	20031222	AU 2003-237394	20030604
PRIORITY APPLN. INFO.:			IN 2002-MA425 A	20020605
			WO 2003-US17672 W	20030604

OTHER SOURCE(S): CASREACT 140:42205
IT 83881-52-1P, Cetirizine dihydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(salification with HCl of)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

L6 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01 Aug 2003
AB A tablet and a process for its manufacture are described where a drug having a defined rate of delivery is applied by compression onto a compressible coating deposited on a tablet having the same or a different in vivo drug release profile. For the compressible coating, an acrylic acid, methacrylic acid, or ester of either is the preferred monomer for making the polymer in the coating. A pseudoephedrine tablet blend was obtained from pseudoephedrine-HCl (crystals) 75.4, Avicel PH101 21.2, Klucel TM 3.4, and water 8%. A 2-kg batch is prepared by first dry mixing the above powders in a high-shear granulator. The water (160 g) is added at 60 g/min, then the sample mixed for an addnl. 30 s to give a total mix time of 8 min. The granulation is then spread on a polyethylene lined tray and dried 16 h at 50°. The granulation is then passed through a mill. A final pseudoephedrine tablet blend (containing 44.9% pseudoephedrine) is prepared by combining the components below without the magnesium stearate at the designated percentages and blending in a V-blender for 15 min followed by an addnl. 5-min after addition of the magnesium stearate; pseudoephedrine granulation- Part.A 59.5, Avicel-PH200 40.0, and Mg stearate 0.5%. A water-permeable compressible coating containing PEG, Eudragit RL, and tri-Et citrate was applied.
ACCESSION NUMBER: 2003:590609 HCAPLUS
DOCUMENT NUMBER: 139:122800
TITLE: Manufacture of tablets containing polymers
INVENTOR(S): Waterman, Kenneth C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 99,715.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003143272	A1	20030731	US 2002-243332	20020913
US 2003039691	A1	20030227	US 2002-99715	20020313
US 2006105040	A1	20060518	US 2006-332005	20060112
PRIORITY APPLN. INFO.:			US 2001-275889P	P 20010314
			US 2002-99715	A2 20020313

IT 83881-52-1, Cetirizine hydrochloride
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(manufacture of tablets containing polymers)
RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Jul 2003
AB Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided. The pharmaceutical is adapted for time-release, or the antagonist comprises an insol. coating, or both. The bioavailability occurs upon mech. disruption. The dosage form is adapted to be administered rectally, parenterally, vaginally, transdermally, intranasally, or via an aerosol.
ACCESSION NUMBER: 2003:511826 HCAPLUS
DOCUMENT NUMBER: 139:74068
TITLE: Pharmaceutical safety dosage forms
INVENTOR(S): Roberts, Richard H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003124061	A1	20030703	US 2003-339977	20030110
CA 2505661	AA	20040729	CA 2003-2505661	20031218
WO 2004062642	A1	20040729	WO 2003-US40990	20031218
WO 2004062642	B1	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003299826	A1	20040810	AU 2003-299826	20031218
EP 1581188	A1	20051005	EP 2003-800100	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514067	T2	20060427	JP 2004-566589	20031218
PRIORITY APPLN. INFO.:			US 2003-339977	A 20030110
			WO 2003-US40990	W 20031218

IT 83881-52-1, Cetirizine hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical safety dosage forms)
RN 83881-52-1 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

L6 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 11 May 2001
AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

ACCESSION NUMBER: 2001:338762 HCAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

IT 83881-51-0, Cetirizine
RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified); BIOL (Biological study)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
RN 83881-51-0 HCAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



10729856

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	94.46	261.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.75	-12.75

STN INTERNATIONAL LOGOFF AT 16:56:07 ON 18 NOV 2006